A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.

Trial Profile

A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs DSM 265 (Primary) ; Mefloquine
  • Indications Malaria
  • Focus First in man; Pharmacodynamics
  • Most Recent Events

    • 01 Jun 2017 Primary endpoint (Parasite clearance kinetics in healthy subjects following a blood stage infection with P. falciparum.) has not been met as per the results published in The Lancet Infectious Diseases
    • 01 Jun 2017 Results published in The Lancet Infectious Diseases
    • 07 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top